Kapitel 32: Grundlagen der medikamentösen Schmerztherapie in der Onkologie

Abel SR. Tramadol. J Pharm Care Pain Symptom Control 3, 5–29, 1995


Ärztliche Zentralstelle Qualitätssicherung. Leitlinien „Schmerztherapie bei Tumorerkrankungen“. München, 2001


Bailie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. Age Aging 7, 186–192, 1988


Boico O, Bonnet F, Rostaing S et al. Epidural clonidine produces postoperative analgesia. Anesthesiology 69, A388, 1988


Broadbent A, Giare P. Neurotoxicity from chronic opioid therapy after successful palliative treatment for painful bone metastases. J Pain Symptom Manage 29, 520–524, 2005


Bruera E, MacEachern T, Macmillan K, Miller MJ, Hanson J. Local tolerance to subcutaneous infusions of high concentrations of hydromorphone. J Pain Symptom Manage 8, 201–204, 1993


Centeno C, Vara F. Intermittent subcutaneous methadone administration in the management of cancer pain. J Pain Palliat Care Pharmacother 19, 7–12, 2005

Coluzzi PH, Schwartzberg L, Conroy JD et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91, 123–130, 2001
Davis MP. Buprenorphine in cancer pain. Support Care Cancer 13, 878–887, 2005
Derra L, Egle UT. Psychosomatik und Psychotherapie. Onkologe 1, 335–342, 1995
Dickinson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C-fibre stimulation. Neuropharmacology 26, 1235–1238, 1987
Donnelly S, Walsh D. The symptoms of advanced cancer. Sem Oncol 22 (Suppl 3), 67–72, 1995
Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl. Pain 64, 527–534, 1996
Eisenach JC, Hood DD, Curry R. Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia. Pain 84, 57–64, 2000
Gourlay GK, Wilson PR, Glynn CJ. Pharmacodynamics and pharmacokinetics of methadone during the periooperative period. Anesthesiology 57, 458–467, 1982
Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53, 805–810, 1981


Kloke M. Gaps and junctions between clinical experience and theoretical framework in the use of opioids. Support Care Cancer 12, 749–751, 2004


Larijani GE, Bell SD, Goldberg ME, Lessin JB. Pharmacokinetics of fentanyl following transdermal application. Anesthesiology 69, A363, 1988

Lauretti GR, Lima IC, Reis MP, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 90, 1528–1533, 1999a

Lauretti GR, Gomes JM, Reis MP, Pereira NL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 11, 663–668, 1999b


Leander JD, McCleary PE. Opioid and nonopioid behavioral effects of methadone isomers. J Pharmacol Exp Ther 220, 592–596, 1982


Lehmann KA. Recent developments in patient-controlled analgesia. J Pain Symptom Manage 29, S72–89, 2005


Lenné MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ. The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 72, 271–278, 2003


Lin JH. Bishosphonates: a review of their pharmacokinetic properties. Bone 18, 75–85, 1996

Lipton A. Bisphosphonates and breast carcinoma. Cancer 80 (Suppl), 1668–1673, 1997


Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides; N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 60, 83–90, 1995


McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev CD005180, 2005
McQuay HJ, Moore RA, Bullingham RES. High systemic relative bioavailability of oral morphine in both solution and sustained release formulation. R Soc Med Intern Congr Symp Ser 60, 149–152, 1984
McQuay HJ, Barden J, Moore RA. Clinically important changes – what's important and whose change is it anyway? J Pain Symptom Manage 25, 395–396, 2003


Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 24 (Suppl 16), 7–12, 1997b


Woodruff R. Palliative medicine – symptomatic and supportive care for patients with advanced cancer and AIDS. Asperula Pty Ltd, Melbourne, 1993


Xiao WH, Bennett GJ. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther 274, 666–672, 1995

Yamamura T, Harada K, Okamura A, Kemmotsu O. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology 72, 704–710, 1990


Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in cancer patients. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004311.pub2